Understanding how different molecular types of pancreatic cancer affect health disparities
Research Project 1 PDAC Molecular Subtypes Contribute to Cancer Health Disparities
['FUNDING_OTHER'] · VIRGINIA COMMONWEALTH UNIVERSITY · NIH-10890850
This study is looking at how differences in pancreatic cancer tumors among different racial groups, especially in Black patients, can affect treatment success and survival, with the goal of finding new ways to help everyone fight this tough cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIRGINIA COMMONWEALTH UNIVERSITY (nih funded) |
| Locations | 1 site (RICHMOND, UNITED STATES) |
| Trial ID | NIH-10890850 on ClinicalTrials.gov |
What this research studies
This research investigates pancreatic ductal adenocarcinoma (PDAC), a severe form of cancer that is particularly aggressive and resistant to treatment. It focuses on how molecular differences in PDAC tumors among various racial groups, especially Black populations, contribute to significant health disparities in incidence and survival rates. By analyzing the unique molecular characteristics of PDAC tumors, the research aims to identify new therapeutic targets that could improve treatment outcomes for affected patients. The study employs advanced techniques like quantitative mass spectrometry to classify PDAC into distinct subtypes and assess their responses to therapies in a racially diverse population.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those from Black populations who are disproportionately affected by this disease.
Not a fit: Patients with pancreatic cancer who do not belong to the racial groups being studied or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer that are tailored to the specific needs of different racial groups, ultimately improving survival rates.
How similar studies have performed: Previous research has successfully identified molecular differences in other cancers that led to improved treatments, suggesting that similar breakthroughs for PDAC are possible.
Where this research is happening
RICHMOND, UNITED STATES
- VIRGINIA COMMONWEALTH UNIVERSITY — RICHMOND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WOODS, NICHOLAS TAYLOR — VIRGINIA COMMONWEALTH UNIVERSITY
- Study coordinator: WOODS, NICHOLAS TAYLOR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer